-60%

est. 2Y upside i

HealthcareSeries C

Science is a clinical-stage medical technology company. We work to restore quality of life to those with debilitating conditions for which there are no treatment options, creating devices aimed at restoring vision, cognition, and mobility to patients who have lost it.

Rank

#3841

Sector

Medical Technology

Est. Liquidity

~4Y

Data Quality

Data: High

Science presents a high-risk, moderate-upside equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (15%)+150%

Science successfully commercializes its PRIMA retinal implant in Europe by mid-2026 and gains accelerated FDA approval, expanding into additional retinal diseases. This market leadership and strong clinical outcomes drive revenue growth, justifying a 2.5x valuation to $3.75 billion, despite competitive pressures.

Base (40%)+20%

Science achieves initial commercialization of PRIMA in Europe, but FDA approval is slower than anticipated, and market penetration faces challenges from well-funded competitors like Neuralink. The company grows modestly, reaching a valuation of approximately $1.8 billion, reflecting steady but not explosive progress.

Bear (45%)-60%

Regulatory delays or unexpected clinical trial setbacks hinder PRIMA's commercialization, or aggressive competition from Neuralink and other BCI players significantly limits market share. High capital burn necessitates a down round, reducing the valuation to $0.6 billion, which, given the substantial liquidation preferences, would severely impair common stock value.

Est. time to liquidity~3.5 years

Preference Stack Risk

severe

Funding Intensity

33%

Investors have contributed $490 million, meaning this amount would be paid out to preferred shareholders before common stock holders see any returns in an exit at or below the current $1.5 billion valuation.

Dilution Risk

high

As a clinical-stage company with very high capital intensity and no current profitability, Science will likely require additional funding rounds, leading to further dilution for existing shareholders.

Secondary Liquidity

limited

Secondary market transactions for Science stock are available only to accredited investors through specific marketplaces and are subject to company approval, limiting liquidity for employees.

View all 13 open roles at Science →

Last updated: February 17, 2026

Questions to Ask at the Interview

Strategic questions based on Science's data — designed to show you've done your homework.

  • 1

    “Given Neuralink's significant funding and broader BCI ambitions, how does Science plan to differentiate and maintain its lead specifically in the retinal implant market, and what is the strategy for expanding into other BCI applications?”

  • 2

    “With a very high capital intensity and being clinical-stage, what are the key milestones for achieving profitability, and what is the projected timeline for reaching positive cash flow?”

  • 3

    “Considering the $490 million in total funding on a $1.5 billion valuation, how is the company thinking about managing future dilution for common shareholders, and what is the philosophy on providing liquidity options (e.g., secondary sales, tender offers) for employees prior to an IPO?”

Community

Valuation Sentiment

Our model estimates -60% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.